Logo image of ASTH

ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis

NASDAQ:ASTH - Nasdaq - US03763A2078 - Common Stock - Currency: USD

31.17  +0.02 (+0.06%)

After market: 31.17 0 (0%)

Fundamental Rating

5

ASTH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. ASTH has only an average score on both its financial health and profitability. ASTH is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ASTH was profitable.
ASTH had a positive operating cash flow in the past year.
ASTH had positive earnings in each of the past 5 years.
Each year in the past 5 years ASTH had a positive operating cash flow.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of 3.18%, ASTH is in the better half of the industry, outperforming 64.71% of the companies in the same industry.
ASTH has a better Return On Equity (6.05%) than 60.78% of its industry peers.
With a decent Return On Invested Capital value of 5.70%, ASTH is doing good in the industry, outperforming 60.78% of the companies in the same industry.
ASTH had an Average Return On Invested Capital over the past 3 years of 7.07%. This is below the industry average of 9.13%.
Industry RankSector Rank
ROA 3.18%
ROE 6.05%
ROIC 5.7%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ASTH's Profit Margin of 2.12% is fine compared to the rest of the industry. ASTH outperforms 60.78% of its industry peers.
ASTH's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 4.39%, ASTH perfoms like the industry average, outperforming 54.90% of the companies in the same industry.
ASTH's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 13.34%, ASTH is not doing good in the industry: 72.55% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 4.39%
PM (TTM) 2.12%
GM 13.34%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ASTH is destroying value.
The number of shares outstanding for ASTH has been increased compared to 1 year ago.
Compared to 1 year ago, ASTH has a worse debt to assets ratio.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 3.72 indicates that ASTH is not in any danger for bankruptcy at the moment.
ASTH has a better Altman-Z score (3.72) than 75.49% of its industry peers.
The Debt to FCF ratio of ASTH is 9.87, which is on the high side as it means it would take ASTH, 9.87 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.87, ASTH is in line with its industry, outperforming 51.96% of the companies in the same industry.
ASTH has a Debt/Equity ratio of 0.60. This is a neutral value indicating ASTH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, ASTH perfoms like the industry average, outperforming 57.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF 9.87
Altman-Z 3.72
ROIC/WACC0.7
WACC8.18%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

ASTH has a Current Ratio of 1.75. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ASTH (1.75) is better than 63.73% of its industry peers.
A Quick Ratio of 1.75 indicates that ASTH should not have too much problems paying its short term obligations.
ASTH has a better Quick ratio (1.75) than 67.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.75
Quick Ratio 1.75
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.58%.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
The Revenue has grown by 46.72% in the past year. This is a very strong growth!
The Revenue has been growing by 38.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-32.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-157.69%
Revenue 1Y (TTM)46.72%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%88.43%

3.2 Future

Based on estimates for the next years, ASTH will show a very strong growth in Earnings Per Share. The EPS will grow by 31.87% on average per year.
Based on estimates for the next years, ASTH will show a quite strong growth in Revenue. The Revenue will grow by 16.54% on average per year.
EPS Next Y51.2%
EPS Next 2Y41.39%
EPS Next 3Y42.01%
EPS Next 5Y31.87%
Revenue Next Year36.87%
Revenue Next 2Y29.09%
Revenue Next 3Y25.88%
Revenue Next 5Y16.54%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 35.02, ASTH can be considered very expensive at the moment.
ASTH's Price/Earnings ratio is in line with the industry average.
ASTH is valuated rather expensively when we compare the Price/Earnings ratio to 28.88, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 23.16, ASTH is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ASTH is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.20, ASTH is valued at the same level.
Industry RankSector Rank
PE 35.02
Fwd PE 23.16
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASTH.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 35.37
EV/EBITDA 14.54
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

ASTH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ASTH's earnings are expected to grow with 42.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.68
PEG (5Y)1.83
EPS Next 2Y41.39%
EPS Next 3Y42.01%

More info and screens

0

5. Dividend

5.1 Amount

ASTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTRANA HEALTH INC

NASDAQ:ASTH (4/30/2025, 8:00:01 PM)

After market: 31.17 0 (0%)

31.17

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners47.59%
Inst Owner ChangeN/A
Ins Owners8.89%
Ins Owner Change-6.15%
Market Cap1.56B
Analysts85.56
Price Target51.46 (65.09%)
Short Float %4.11%
Short Ratio4.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP9.35%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-111.71%
Min EPS beat(2)-225.16%
Max EPS beat(2)1.74%
EPS beat(4)3
Avg EPS beat(4)-55.53%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)6
Avg EPS beat(8)-12.72%
EPS beat(12)9
Avg EPS beat(12)1.75%
EPS beat(16)13
Avg EPS beat(16)12.21%
Revenue beat(2)2
Avg Revenue beat(2)3.58%
Min Revenue beat(2)1.5%
Max Revenue beat(2)5.66%
Revenue beat(4)3
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-4.21%
Max Revenue beat(4)8.16%
Revenue beat(8)5
Avg Revenue beat(8)1.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.99%
PT rev (3m)-21.78%
EPS NQ rev (1m)-21.31%
EPS NQ rev (3m)-24.73%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)-10.14%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)1.78%
Revenue NY rev (1m)0.84%
Revenue NY rev (3m)1.95%
Valuation
Industry RankSector Rank
PE 35.02
Fwd PE 23.16
P/S 0.77
P/FCF 35.37
P/OCF 29.93
P/B 2.19
P/tB 8.91
EV/EBITDA 14.54
EPS(TTM)0.89
EY2.86%
EPS(NY)1.35
Fwd EY4.32%
FCF(TTM)0.88
FCFY2.83%
OCF(TTM)1.04
OCFY3.34%
SpS40.59
BVpS14.22
TBVpS3.5
PEG (NY)0.68
PEG (5Y)1.83
Profitability
Industry RankSector Rank
ROA 3.18%
ROE 6.05%
ROCE 9.03%
ROIC 5.7%
ROICexc 8.07%
ROICexgc 35.01%
OM 4.39%
PM (TTM) 2.12%
GM 13.34%
FCFM 2.17%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score4
Asset Turnover1.5
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF 9.87
Debt/EBITDA 3.63
Cap/Depr 28.76%
Cap/Sales 0.39%
Interest Coverage 2.94
Cash Conversion 44.51%
Profit Quality 102.36%
Current Ratio 1.75
Quick Ratio 1.75
Altman-Z 3.72
F-Score4
WACC8.18%
ROIC/WACC0.7
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-157.69%
EPS Next Y51.2%
EPS Next 2Y41.39%
EPS Next 3Y42.01%
EPS Next 5Y31.87%
Revenue 1Y (TTM)46.72%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%88.43%
Revenue Next Year36.87%
Revenue Next 2Y29.09%
Revenue Next 3Y25.88%
Revenue Next 5Y16.54%
EBIT growth 1Y5.59%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year82.75%
EBIT Next 3Y45.19%
EBIT Next 5Y30.92%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A